Pfizer Inc. (PFE)
Pfizer Crosses Below Key Moving Average Level
In trading on Thursday, shares of Pfizer crossed below their 200 day moving average of $24.58, changing hands as low as $24.28 per share. Pfizer shares are currently trading off about 1.6% on the day.
Pfizer: Is This Pharma Giant Finally A Bargain
Following Pfizer's victory over Novo Nordisk in the "war" for Metsera, its stock resumed its upward momentum. But before the deal was completed, it again beat Wall Street analysts' consensus EPS and revenue estimates by a wide margin. Lorbrena, an ALK inhibitor against non-small cell lung cancer, brought in $268 million for Pfizer in Q3, up 30.1% year-on-year.
Pfizer Inc. (PFE) Presents at Jefferies London Healthcare Conference 2025 Transcript
Pfizer Inc. ( PFE ) Jefferies London Healthcare Conference 2025 November 19, 2025 4:00 AM EST Company Participants David Denton - Executive VP & CFO Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Presentation Akash Tewari Jefferies LLC, Research Division Good morning, everyone. I hope you're all doing well.
Pfizer Trading Above 50-Day SMA: Is it a Good Time to Buy the Stock?
PFE trades above its 50-day SMA on recent gains from the Metsera acquisition and a drug pricing agreement with the U.S. administration.
Activist Starboard sells Pfizer stake after pushing for changes
Activist investor Starboard Value has liquidated its position in Pfizer , according to a regulatory filing on Friday, ending its push for changes aimed at boosting the drugmaker's share price.
Pfizer Inc. (PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology Transcript
Pfizer Inc. ( PFE ) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology November 10, 2025 8:30 AM EST Company Participants Francesca DeMartino - Chief Investor Relations Officer Jeff Legos Johanna Bendell - Chief Development Officer of Oncology Arati Rao Conference Call Participants Steve Scala - TD Cowen, Research Division Evan Seigerman - BMO Capital Markets Equity Research Jiexian Zhuang - Leerink Partners LLC, Research Division Ethan Brown - JPMorgan Chase & Co, Research Division Presentation Operator Good day, everyone, and welcome to Pfizer Pflash, a spotlight on the PD-1 VEGF bispecific PF-4404 clinical development strategy. Today's call is being recorded.
Pfizer Wins Obesity War Against NVO, to Buy Metsera for Around $10B
Pfizer secures a $10B deal to buy Metsera, ending its fierce bidding war with Novo Nordisk and reigniting its push into the obesity market.
Pfizer to buy Metsera in deal worth up to $10 billion
Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk. Metsera accepted a sweetened offer from Pfizer late on Friday, citing U.S. antitrust risks in Novo's bid that it had previously called superior.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
5 Things to Know Before the Stock Market Opens
Stock futures are surging this morning after U.S. lawmakers passed a key procedural hurdle as part of an agreement that could bring an end to the shutdown that has lasted nearly six weeks; President Donald Trump has proposed issuing $2,000 “dividend” checks to Americans that would be funded by revenue from tariffs; AI data center firm CoreWeave (CRWV) is set to release its quarterly results after the closing bell today; and shares of Metsera (MTSR) are plunging after the weight-loss drug maker announced that it would be acquired by Pfizer (PFE) after a bidding war with Novo Nordisk (NVO). Here's what you need to know today.
U.S. Senate Makes Progress on Shutdown Deal, Novo Nordisk Loses Out to Pfizer
The U.S. Senate progressed a deal towards ending the longest U.S. Government shutdown in history. Eight democrats joined all but one republican in voting to move forward with a funding bill that will keep the U.S. Government liquid through January 30th, drawing rebuke from Democratic party leaders given the deal's lack of guarantees on healthcare.
Pfizer has agreed to buy weight-loss drug startup Metsera in a deal that could be worth more than $10 billion, besting rival Novo Nordisk following a heated bidding war
Pfizer prevails over rival Novo Nordisk after an unusual bidding war for the weight-loss startup.
